DRMA — Dermata Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-08-13.
Performance
Technicals
Others in Healthcare
Measured signals that fired on DRMA
| date | signal | measured base rate |
|---|---|---|
| 2026-03-30 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-16 | PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO | Grant or award | 170.1K | — | — |
| 2026-08-16 | Van Hoose Kyri K. SVP, CFO | Grant or award | 102.0K | — | — |
| 2026-06-16 | Scott Kathleen D. Director | Open-market sale | 11 | 1.19 | 13 |
| 2026-02-17 | Bedoya-Toro Munera Maria E SVP, Regulatory Affairs | Open-market purchase | 1.0K | 1.27 | 1.3K |
| 2025-12-23 | PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO | Grant or award | 122.5K | — | — |
| 2025-12-23 | Van Hoose Kyri K. SVP, CFO | Grant or award | 122.5K | — | — |
| 2025-12-23 | PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO | Grant or award | 490.2K | — | — |
| 2025-01-23 | HALE DAVID F Director | Grant or award | 78.7K | — | — |
| 2025-01-21 | FISHER MARY Director | Grant or award | 196.9K | — | — |
| 2025-01-21 | Van Hoose Kyri K. SVP, CFO | Grant or award | 78.7K | — | — |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 58.5K | 48.3K |
| UBS Group AG | 43.1K | 35.6K |
| Welch & Forbes LLC | 24.2K | 20.0K |
| MCF Advisors LLC | 2.1K | 1.7K |
| Tower Research Capital LLC (TRC) | 866 | 716 |
| SBI Securities Co., Ltd. | 122 | 101 |
| CITIGROUP INC | 1 | 1 |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 8-K | 2026-08-17 | 2026-08-16 | on EDGAR ↗ |
| 25-NSE | 2026-08-17 | — | on EDGAR ↗ |
| 10-Q | 2026-08-11 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-11 | 2026-08-11 | on EDGAR ↗ |
| 8-K | 2026-08-05 | 2026-08-05 | on EDGAR ↗ |
| 4 | 2026-06-16 | 2026-06-16 | on EDGAR ↗ |
| S-8 | 2026-06-04 | — | on EDGAR ↗ |
| SCHEDULE 13D | 2026-06-01 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Dermata Therapeutics, Inc. (DRMA) filed form 8-K · 2026-08-17 · SEC EDGAR
- Dermata Therapeutics, Inc. (DRMA) filed form 8-K · 2026-08-11 · SEC EDGAR
Ask the AI about DRMA
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →